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Summary
Background Escherichia coli is a leading cause of bloodstream infections. Developing interventions to reduce E coli 
infections requires an understanding of the frequency of nosocomial transmission, but the available evidence is 
scarce. We aimed to detect and characterise transmission of E coli and associated plasmids in a hospital setting.
Methods In this prospective observational cohort study, patients were admitted to two adult haematology wards at the 
Cambridge University Hospitals NHS Foundation Trust in England. Patients aged 16 years and older who were 
treated for haematological malignancies were included. Stool samples were collected from study participants on 
admission, once per week, and at discharge. We sequenced multiple E coli isolates (both extended spectrum 
β-lactamase [ESBL]-producing and non-ESBL-producing) from each stool sample. A genetic threshold to infer 
E coli transmission was defined by maximum within-host single nucleotide polymorphism (SNP) diversity and the 
probability of drawing observed pairs of between-patient isolates at different SNP thresholds. Putative transmission 
clusters were identified when sequences were less than the genetic threshold. Epidemiological links for each 
transmission event were investigated. We sequenced all E coli positive blood samples from the two adult 
haematology wards.
Findings We recruited 174 (51%) of 338 adult patients admitted to the wards between May 13 and Nov 13, 2015. We 
obtained and cultured 376 stool samples from 149 patients, of which 152 samples from 97 (65%) patients grew E coli. 
Whole-genome sequencing was done on 970 isolates. We identified extensive diversity in the bacterial population 
(90 sequence types) and mixed E coli sequence type carriage. 24 (26%) patients carried two sequence types, 12 (13%) 
carried three, and six (6%) patients carried four or more sequence types. Using a 17 SNP cutoff we identified ten 
clusters in 20 patients. The largest cluster contained seven patients, whereas four patients were included in multiple 
clusters. Strong epidemiological links were found between patients in seven clusters. 17 (11%) of 149 patients had 
stool samples positive for ESBL-producing E coli, the most common of which was associated with blaCTX-M-15 
(12 [71%] of 17). Long-read sequencing revealed that blaCTX-M-15 was often integrated into the chromosome, with little 
evidence for plasmid transmission. Seven patients developed E coli bloodstream infection, four with identical strains 
to those in their stool; two of these had documented nosocomial acquisition.
Interpretation We provide evidence of bacterial transmission and endogenous infection during routine care by 
integrating genomic and epidemiological data and by determining a genetic cutoff informed by within-host diversity 
in the studied population. Our findings challenge single colony-based investigations, and the widely accepted notion 
of plasmid spread.
Funding UK Department of Health, Wellcome Trust, UK National Institute for Health Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Escherichia coli is one of the leading causes of bloodstream 
and urinary tract infections, a proportion of which 
are health-care associated.1 Rates of E coli bloodstream 
infections have markedly increased in numerous 
countries, such as England, where the incidence rose 
from 60·4 per 100 000 population (32 309 reported cases) 
in 2012–13, to 77·3 per 100 000 population (43 209 reported 
cases) in 2019–20.1 This rate has increased from 76·6 
to 121·6 per 100 000 population at Cambridge University 
Hospitals in England within the same period.2 This 
problem is compounded by a global increase in the 
frequency of E coli infections caused by strains that are 
resistant to numerous antibiotics, which are associated 
with excess morbidity, mortality, longer hospital stays, 
and higher health-care costs.3–6
Interventions to support a reduction in health-care 
asso ciated bloodstream infections caused by E coli require 
an understanding of the frequency of nosocomial 
transmission, but the available evidence remains scarce. 
Previous studies7–9 that used bacterial sequencing, an 
essential tool that provides the necessary genetic 
resolution, were done on small cohorts or included solely 
extended spectrum β-lactamase (ESBL)-producing E coli 
or specific sequence types, which were more likely to 
under-represent transmission of E coli overall (ie, including 
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both ESBL-producing and non-ESBL-producing E coli). 
Furthermore, transmission studies require an under-
standing of the frequency of mixed strain E coli carriage 
and within-host diversity of the same lineage.
The aim of this study was to report findings from 
genomic surveillance of E coli in two haematology 
hospital wards.
Methods
Study design and participants
We did a prospective observational cohort study of 
patients admitted to two adult haematology wards at 
the Cambridge University Hospitals NHS Foundation 
Trust in England. We evaluated E coli acquisition and 
trans mission in patients aged 16 years and older, who 
were treated for haematological malignancies. Patients 
younger than 16 years and those not treated for 
haematological malignancies were excluded. All patients 
provided written informed consent. The same cohort was 
previously studied to investigate the transmission of 
Klebsiella pneumoniae and Enterococcus faecium.10,11 The 
study protocol (appendix 1 pp 2–6) was approved by 
the National Research Ethics Service (14/EE1123 and 
12/EE/0439) and the Cambridge University Hospitals 
NHS Foundation Trust (A093285 and A092685).
Procedures
Hospital admission and bed movement data were 
extracted electronically using the hospital bed tracking 
system. Admission to the same bay, room, or ward at 
the same time or within 7 days was classified as a strong 
epidemiological link; admission in the same ward 
separated by more than 7 days or to the study hospital but 
to different wards (regardless of admission dates) 
was classified as a weak epidemiological link; and no 
epidemiological link was reported if neither of these 
occurred. After enrolment, patients provided stool 
samples during admission and then once a week until 
discharge. Samples were enriched in Tryptic Soy Broth 
(Sigma, Dorset, UK) and directly cultured onto Brilliance 
UTI Chromagar (Oxoid, Basingstoke, UK) to detect all 
E coli and onto Brilliance ESBL agar (Oxoid, Basingstoke, 
UK) to detect ESBL E coli. Up to 15 E coli colonies 
(ten putative ESBL-producing and five non-ESBL-
producing), cultured from each stool sample, were 
selected for sequencing (appendix 1 p 2). For stool 
Research in context
Evidence before this study
We searched PubMed for studies published in English from 
database inception to March 17, 2020, using the terms 
“Escherichia coli”, “whole genome sequencing”, “transmission”, 
and “hospital”. We excluded reviews and included articles in 
which whole-genome sequencing was applied to study E coli 
transmission in human populations in a hospital setting 
(15 of 75 studies). 12 of 15 studies were focused on carbapenem 
or colistin resistance and were not evaluated further. Of the 
three remaining studies, one focused on the national 
epidemiology of a single clone (ST410) in Denmark and was 
based on 127 whole-genome sequenced isolates. Five possible 
regional outbreaks were identified using ten or less single 
nucleotide polymorphisms (SNPs). In a second study done in 
Denmark, whole-genome multilocus sequence typing (MLST) 
was used to distinguish between epidemiologically related 
and unrelated isolates of extended spectrum β-lactamase 
(ESBL)-producing E coli. Isolates obtained from the same patient, 
belonging to the same MLST, and cultured within 30 days were 
defined as epidemiologically related. In a third study, 
transmission of E coli among patients in haematology and 
oncology departments of German hospitals was investigated 
using core-genome MLST, in which closely related isolates were 
defined as having a maximum of ten allele differences.
Added value of this study
Our findings capture what happens during routine care, beyond 
the current bacterial genomics literature which largely focuses on 
outbreak investigations. We show that surveillance and outbreak 
investigations based on single colonies are likely to 
underestimate transmission events and the diversity of 
antimicrobial susceptibility profiles present in a sample. 
Our study also adds to the existing evidence on suitable methods 
to determine transmission events. We established a genome-
based SNP threshold to infer E coli transmission in the study 
population by comparing SNP distances of isolates from the same 
host and combining these with epidemiological data. 
We identified transmission clusters involving predominately 
patients with non-ESBL E coli, which would be missed by other 
investigations focused on antimicrobial-resistant E coli. Using 
long-read sequencing, we were able to accurately study the 
transmission of antimicrobial resistance genes conferring 
resistance to cephalosporin drugs (ESBLs) and plasmids. Although 
E coli from patients carried the same genes conferring resistance, 
the genes were rarely carried on the same plasmids as those 
found in other patient samples. This finding would not have been 
identified using short-read sequencing. By comparing E coli 
isolates from blood and stool samples of individual patients we 
identified indistinguishable isolates, suggesting endogenous 
infection.
Implications of all the available evidence
Our study highlights polyclonal E coli colonisation, the 
pathogenesis of extraintestinal E coli infection (endogenous vs 
exogenous), and the clinical relevance of E coli transmission in 
the hospital setting. Our findings challenge the widely accepted 
notion of plasmid spread, at least for E coli, in this setting. 
Interventions to reduce E coli bacteraemia should aim to 
prevent endogenous infections, which were the main 
source of infection.
See Online for appendix 1
Articles
www.thelancet.com/microbe   Vol 2   September 2021 e474
For ISFinder see https://isfinder.
biotoul.fr 
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For the EnteroBase see https://
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samples that grew fewer than 15 E coli colonies, all of the 
available colonies were sequenced.
During the 6-month study, any blood cultures taken 
from the patient cohort based on clinical need were 
identified in the diagnostic laboratory. If the sample grew 
E coli, the primary subculture plate was identified and 
retrieved from the diagnostic laboratory and up to 
12 colonies were picked for sequencing. Hospital 
acquired and health-care associated infections were 
based on definitions by Friedman and colleagues.12 
Additionally, we retrospectively identified all blood 
cultures positive for E coli in patients residing in the two 
haematology wards in the 12 months before this study 
(between May 13, 2014, and May 13, 2015) and 6 months 
after (between Nov 13, 2015, and May 13, 2016), from 
which one colony was obtained for sequencing from the 
culture in the freezer archive. Further details on culture 
protocols, selection of colonies, and antimicrobial 
susceptibility testing are shown in appendix 1 (p 2). The 
number of invasive infections per 1000 admissions was 
determined from the number of recruited patients 
admitted to haematology wards.
The objectives of this study were to measure within-
host E coli diversity, identify potential clusters of E coli 
transmission between patients at the study sites, and 
identify associated plasmids encoding antimicrobial 
resistance genes in this setting.
Sequencing and bioinformatic analyses
DNA was extracted, libraries prepared, and sequenced on 
an Illumina HiSeq2000 (San Diego, CA, USA) with 
125 cycle paired-end reads. Following quality control, 
genomes were assembled using SPAdes (version 3.11.0) 
and mapped against the E coli reference strain (GenBank: 
LT632320) using SMALT (version 0.7.4).13 In-silico sequence 
type identification of all sequenced isolates was done using 
the EnteroBase MLST sequence archive. Sequencing and 
bioinformatic methods are described in appendix 1 (p 3). 
The core genome was derived using Roary (version 1.7.1) 
using the “don’t split paralogs” option.14 Whole-genome 
alignments were created by calling nucleotide alleles along 
the E coli LT632320 reference genome and pairwise single 
nucleotide poly morphism (SNP) distances in core genome 
alignments using pairsnp (appendix 1 pp 3–4). The 
core genome coordinates are publicly available. SNP 
distances cannot be compared with whole-genome SNP 
differences, but should be comparable with the distances 
reported using the same reference genome and coordinates 
used in this study. The genomes of multiple E coli isolates 
from the same patient were used to ascertain E coli 
within-host diversity for all participants and subsequently 
determine an appropriate threshold to define transmission 
of E coli sequence types between patients. The analysis was 
limited to instances in which different patients shared the 
same sequence type. The upper limit for a SNP cutoff was 
provisionally established from the maximum within-host 
diversity (the number of core genome differences in 
isolates of the same sequence type from the same patient), 
which defines the upper limit of transferable diversity 
from one person to another. The SNP cutoff was validated 
using a statistical approach, as described in appendix 1 
(pp 4–5). The cutoff was applied to all pairs of sequences to 
identify putative transmission and was subsequently 
complemented with epidemiological information.
Detection of antimicrobial resistance and mobile 
elements
Antimicrobial susceptibility testing was determined for 
all isolates using the N206 card on the Vitek 2 instrument 
(bioMérieux, Marcy l’Étoile, France), calibrated against 
EUCAST breakpoints. Detailed methods to detect 
antimicrobial resistance genes and the rationale for 
selecting isolates for long-read sequencing to investigate 
plasmid sharing between patients are shown in 
appendix 1 (p 5). Briefly, E coli genomes from all 
participants were screened for acquired genes encoding 
antibiotic resistance using Antibiotic Resistance Identifi-
cation By Assembly (ARIBA; version 2.13.3).15 Chromo-
somal mechanisms of fluoroquinolone resistance 
were identified by screening isolates for the presence of 
associated amino acid changes in the quinolone 
resistance-determining regions of gyrA and parC 
alleles.16,17 To investigate whether plasmids encoding 
ESBL genes were shared between patients during the 
study, one blaCTX-M-15-positive and blaCTX-M-14-positive isolate 
from each sequence type was selected for long-read 
sequencing using the PacBio Sequel instrument 
(appendix 1 p 5). In-silico PCR was used for plasmid 
incompatibility group (replicon) typing.18 Geneious 
(version 11.1) was used for manual annotation and 
visualisation of complete plasmid sequences. ISFinder 
and the Basic Local Alignment Search Tool (BLAST; 
version 2.9.0) were used to identify insertion sequences 
and transposon fragments. BLAST comparisons 
visualised in the Artemis Comparison Tool (version 17.0.1) 
were used for plasmid comparisons (appendix 1 p 5).
Statistical analysis
The number of positive and negative cultures was 
assessed in patients who received antimicrobials in the 
previous 30 days, versus those who did not, with a 
two-tailed Fisher’s exact test using R (version 3.6.3). 
Using R, a Mann Whitney U test was done to assess the 
difference in the number of sequenced colonies per stool 
sample between those with one sequence type and those 
with multiple sequence types. Plots were created using 
ggplot2 (version 3.3.1). To further validate the SNP 
threshold, we used a statistical approach that compared a 
range of cutoff values (appendix 1 pp 5–6).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
For pairsnp see https://github.
com/gtonkinhill/pairsnp
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Results
We recruited 174 (51%) of 338 adult patients admitted to 
the haematology ward betweeen May 13 and Nov 13, 2015. 
Of the 174 participants, 92 (53%) were male and 82 (47%) 
were female, with a median age of 61 years (IQR 49–69; 
range 19–94  years). Patient characteristics are shown in 
appendix 1 (p 9).11 Most patients (149 [86%]) were able to 
provide at least one stool sample. 101 patients provided 
two or more samples. A total of 376 stool samples were 
collected with a median of three samples (IQR 2–5) 
per patient. This subset of 149 patients formed the basis 
for all further analyses. Patients had a median age of 
61 years (49–69), with 281 admissions in total (a median 
of one admission [1–2]), and stayed a median of 16 days 
(7–27) in hospital, as described previously.10 97 (65%) 
patients had at least one stool positive for E coli, with a 
total of 152 positive stool samples identified. Most patients 
(80 [82%] of 97) with positive samples carried only non-
ESBL-producing E coli, five (5%) carried only ESBL-
producing E coli, and 12 (12%) carried both (figure 1).
114 (77%) patients received antimicrobials in the 
30 days before or during enrolment, or both, including 
47 (90%) of 52 patients with a negative E coli stool culture 
and 67 (69%) of 97 patients with a positive culture 
received antimicrobials in the previous 30 days or at 
enrolment, or both (p=0·00036; appendix 1 p 6).
To assess E coli diversity and putative acquisition, we 
picked a median of five E coli colonies (IQR 5–5; 
range 1–15; hereafter termed isolates) from each of the 
152 primary stool culture plates from 97 patients positive 
for E coli. Overall, whole-genome sequencing was 
done on 970 isolates (686 non-ESBL-producing and 
284 ESBL-producing E coli). From these isolates we 
identified 90 different sequence types (appendix 1 pp 9, 13; 
appendix 2 p 1). The most frequently identified sequence 
types were ST131 (n=14 patients), ST10 (n=9), and ST69 
(n=8; appendix 1 p 13), and accounted for 232 (24%) of 
970 isolates. 17 (11%) of 149 patients had stool samples 
positive for ESBL-producing E coli, with variation in the 
presence of genes encoding ESBLs between different 
sequence types (appendix 1 p 9; appendix 2 p 1). Only 
blaCTX-M-14 and blaCTX-M-15 were present in two or more 
patients. E coli encoding blaCTX-M-15 was isolated from stools 
of 12 patients and blaCTX-M-14 from stools of two patients.
To quantify the amount of within-host E coli diversity, 
we determined the number of different E coli sequence 
types identified from each patient using data on 149 stool 
samples from 94 patients (excluding three stools from 
patients for whom only a single E coli colony was 
isolated). Around half (52 [55%]) of 94 patients were 
positive for a single sequence type. 24 (26%) patients 
carried two sequence types, 12 (13%) carried three, and 
six (6%) patients carried four or more sequence types, 
with a maximum of eight sequence types found in a 
single patient (figure 2). In a per stool analysis, 104 (70%) 
of 149 stools contained a single sequence type, 35 (23%) 
contained two sequence types, and ten (7%) contained 
more than two sequence types, with a maximum of 
five sequence types recovered from a single stool. Of the 
149 stool samples with multiple isolates sequenced, 
104 (70%) contained isolates of the same sequence type, 
and 45 samples (30%) contained more than one sequence 
type. There was no significant difference in the number 
of colonies picked from samples containing a single 
sequence type (median 5 colonies [IQR 5–5]) and those 
with multiple sequence types (median 5 [5–14]; 95% CI of 
the difference between the medians –2·82 × 10–⁵ to 
–7·15 × 10–⁷; p=0·098).
We then identified sequence types that were isolated 
from stools obtained from two or more patients, which 
revealed that 27 sequence types were carried by at least 
two patients. We questioned whether this finding 
represented coincidental carriage of the same sequence 
type or transmission from one patient to another. 
Acquisition analysis was possible for 71 (70%) of 
101 patients who provided at least two stool samples during 
the study and had at least one positive sample for E coli. 
Figure 1: Description of study participants and Escherichia coli culture
ESBL=extended spectrum β-lactamase.
Figure 2: Number of Escherichia coli sequence types observed per patient (n=92)
338 patients admitted
174 patients enrolled
25 enrolled patients did not provide 
a stool sample
149 patients provided at least one stool sample 
(376 stool samples in total)
97 patients positive for E coli
80 patients positive for non-ESBL-producing E coli only
5 patients positive for ESBL-producing E coli only
12 patients positive for types of  E coli
52 patients negative for E coli
48 patients provided one stool sample
101 patients provided ≥2 stool samples
164 patients were not enrolled

















Number of sequence types per patient
See Online for appendix 2
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30 (42%) patients had putative acquisition of one or more 
E coli sequence types through 50 acquisition events 
(appendix 1 p 9; appendix 2 p 2). Of the 17 patients positive 
for ESBL-producing-E coli, 13 (76%) were positive for 
ESBL-producing-E coli on their first stool sample, whereas 
four (24%) had tested positive on follow-up sampling 
indicating that putative acquisition of ESBL-producing-E coli 
occurred during hospital admission.
We used sequence data to define a cutoff of genetic 
similarity between two genomes that was consistent with 
E coli transmission in the population studied. A core 
genome pairwise comparison of isolates from the same 
patient and same sequence type showed a maximum 
diversity of 17 SNPs (6·8 SNPs per million bases; 
figure 3), with the exception of three patients who carried 
isolates which belonged to distinct clades of the same 
sequence type (different by >300 SNPs, appendix 1 p 9; 
appendix 2 p 3). The Poisson distribution indicated an 
upper limit of 25 SNPs (appendix 1 p 14). Having defined 
two putative but different cutoffs of 17 and 25 SNPs, we 
used epidemiological information to select the final 
proposed cutoff. We found that patient pairs with a 
strong epidemiological link (same bay, room, or ward at 
the same time or within 7 days) carried isolates that were 
up to 17 SNPs different, whereas patient pairs carrying 
isolates 17 to 25 SNPs apart did not have strong 
epidemiological links. Thus, we selected a 17 SNP cutoff, 
appreciating that this cutoff is probably more specific but 
less sensitive than 25 SNPs.
We then applied the 17 SNP cutoff to all 970 E coli isolates, 
reflecting a strictly genomic investigation of putative 
transmission. We identified ten clusters (defined as 
containing two or more cases) in 20 patients, four of whom 
were placed in multiple clusters (table 1; appendix 1 p 15). 
Strong epidemiological links were found between patients 
in seven clusters (appendix 1 p 15). The two largest clusters 
contained seven patients associated with sequence type 
ST7095 and four patients associated with sequence type 
ST635 (phylogenetic trees and timelines shown in 
appendix 1 pp 16–19). These sequence types seemed to 
have been acquired after admission to hospital (six patients 
for ST7095 and two for ST635), further supporting hospital 
acquisition. The remaining eight clusters contained 
two patients each and were associated with eight different 
sequence types (ST69, ST131, ST443, ST648, ST1193, 
ST1196, ST6151, and ST7094).
A serious consequence of E coli carriage is the 
development of a bloodstream infection, which occurred 
Figure 3: Histogram of maximum pairwise SNP distance (n=92)
SNP differences within sequence types from the same patient when at least 
two isolates of the same sequence type were identified. There were no data 
points at 31–60 days. SNP=single nucleotide polymorphism.

























C011 ST7095 Yes First case detected
C016 ST7095 Yes 2–6
C095 ST7095 Yes 2–3
C098 ST7095 Yes 0–2
C100 ST7095 Yes 5–7
C104 ST7095 Yes 2–4
D058 ST7095 No 1–3
Cluster 2
D013 ST635 No First case detected
C100 ST635 Yes 0
D038 ST635 No 3
D045 ST635 Yes 1–2
Cluster 3
C031 ST1193 No First case detected
C043 ST1193 Yes 0–2
Cluster 4
C023 ST1196 No First case detected
C035 ST1196 No 0–7
Cluster 5
C022 ST131 No First case detected
C027 ST131 No 0
Cluster 6
C043 ST6151 No First case detected
C031 ST6151 Yes 0–2
Cluster 7
C031 ST648 No First case detected
C043 ST648 Yes 0–1
Cluster 8
C096 ST69 No First case detected
C100 ST69 Yes 0–1
Cluster 9
C059 ST7094 No First case detected
D058 ST7094 Yes 0–1
Cluster 10
C005 ST443 No First case detected
D030 ST443 No 8–11
Patient identification codes are indicated within each cluster. SNP=single 
nucleotide polymorphism. *Patients were previously negative for E coli or 
acquired a new sequence type. †SNP distance range refers to the minimum–
maximum SNPs between the isolate from that patient and others in the cluster.
Table 1: Ten patient clusters from genomic analysis of Escherichia coli 
stool isolates
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in nine (5%) of 174 patients (281 admissions; 
appendix 1 pp 10–11) during the study period, equating 
to around 32 invasive infections per 1000 admissions. 
All nine patients had a bloodstream infection associated 
with health-care contact (four hospital acquired and five 
health-care associated). Seven patients were infected by 
non-ESBL-producing E coli and two by ESBL-producing 
E coli. Seven patients had at least one positive stool 
cultured and the other two did not provide a stool 
sample. Four patients provided a stool sample before 
infection onset. We sequenced 100 colonies from 
12 stools from the seven patients (median 15 colonies 
per patient; range 5–30). The same sequence type was 
identified in blood and stool samples in four patients 
(two with ST131, one with ST95, and one with ST1193). 
Pairwise core genome comparison of these stool and 
disease-associated E coli genomes showed that the blood 
and stool isolates were very highly related (difference 
of 0 SNPs).
Over a longer timeframe (from May 13, 2014, to 
May 13, 2016), we identified 36 additional positive blood 
cultures from the same two study wards (from 
25 patients) with at least one E coli isolate available for 
sequencing. The E coli isolates belonged to 18 sequence 
types, with nine (25%) isolates being ST131 and 12 (33%) 
ESBL-producing E coli. Details of all E coli isolates 
sequenced from bloodstream infections are shown in 
appendix 2 (p 1).
34 (23%) of 149 patients had E coli resistant to 
ciprofloxacin in stool isolates and the mechanisms 
of resistance were identified (appendix 1 pp 11; 
appendix 2 p 4). The types of ESBL-encoding genes we 
identified and sequence types carrying each type are 
shown in appendix 1 (pp 7, 9) and appendix 2 (p 1). We 
selected 31 ESBL-producing E coli isolates (21 stool and 
ten blood cultures) for long-read sequencing. In half of 
E coli blaCTX-M-15 cases (eight of 16), the gene was integrated 
into the chromosome rather than carried on a plasmid, 
with one further patient carrying an isolate with the gene 
on both the chromosome and a plasmid. Chromosomal 
insertion of blaCTX-M-15 occurred across four STs (ST131, 











Phenotypic resistance* Antimicrobial resistance 
genes on plasmid
LR595882 3546 B005† Blood 648 152 153 IcFIA, IncFIB, IncFII Cefotaxime, ceftazidime, amoxicillin, 
ciprofloxacin, gentamicin, piperacillin 
with tazobactam
blaCTX-M-15; blaTEM-1; aac(3)-IIa; 
dfrA17; sul1; tetB; mphA; 
aadA5; strAB; ermB
LR595874 3547 B005† Blood 648 152 153 IcFIA, IncFIB, IncFII Cefotaxime, ceftazidime, amoxicillin, 
ciprofloxacin, gentamicin, piperacillin 
with tazobactam
blaCTX-M-15; blaTEM-1; aac(3)-IIa; 
dfrA17; sul1; tetB; mphA; 
aadA5; strAB; ermB
LR595875 3580 B006† Blood 131 111 743 IncFIB Cefotaxime, ceftazidime, amoxicillin, 
gentamicin
blaCTX-M-15
LR595876 3550 C042† Blood 2006 170 000 IncFIA, IncFIB, IncFII Cefotaxime, ceftazidime, amoxicillin, 
ciprofloxacin, gentamicin
blaCTX-M-15; blaOXA-1; aac(3)-IIa; 
aac6_prime-Ib-cr; dfrA17; sul1; 
tetB; mphA; aadA5
LR595878 3271 C025 Stool 1723 111 381 IncFIB Cefotaxime, ceftazidime, ciprofloxacin blaCTX-M-15
LR595886 2898 C065 Stool 131 164 328 IncFIA, IncFII, IncN Cefotaxime, ceftazidime, ciprofloxacin blaCTX-M-15; blaOXA-1; aac6_prime-Ib-
cr; dfrA17; sul1; mphA; aadA5; 
tetA
LR595884 2981 C071 Stool 131 61 991 IncFIA, IncFIB Cefotaxime, ceftazidime, amikacin, 
amoxicillin, ciprofloxacin, gentamicin
blaCTX-M-15; blaOXA-1; aac(3)-IIa; 
aac6_prime-Ib-cr; dfrA17; sul1; 
mphA; aadA5; tetA(x2); strAB
LR595879 3060 C071 Stool 131 69 882 IncFIA, IncFIB Cefotaxime, ceftazidime, amikacin, 
amoxicillin, ciprofloxacin, gentamicin, 
piperacillin with tazobactam
blaCTX-M-15; blaOXA-1(x2); aac(3)-IIa; 
aac6_prime-Ib-cr; dfrA17; sul1; 
mphA; aadA5; tetA(x3); strAB
LR595890 2766 D038 Stool 1723 111 381 IncFIB Cefotaxime, ceftazidime,
ciprofloxacin
blaCTX-M-15
LR595881 3125 D050 Stool 7097 81 285 IncFIB Cefotaxime, ceftazidime blaCTX-M-15; qnrS1; dfrA14; sul2; 
blaTEM-1
LR595877 2656 C047 Blood 156 111 594 IncB/O/K/Z Cefotaxime, gentamicin blaCTX-M-14; aac(3)-IIa; dfrA17; 
sul1; mphA; aadA5
LR595889 2604 C047 Blood 428 94 296 IncB/O/K/Z Cefotaxime blaCTX-M-14
LR595871 2656 C047 Blood 428 94 061 IncB/O/K/Z Cefotaxime blaCTX-M-14
LR595888 2887 C062 Stool 3877 96 306 IncB/O/K/Z Cefotaxime blaCTX-M-14
LR595880 2978 C062 Blood 131 96 305 IncB/O/K/Z Cefotaxime, amoxicillin, ciprofloxacin, 
gentamicin
blaCTX-M-14
LR595872 3877 C062 Stool 3877 96 306 IncB/O/K/Z Cefotaxime, amoxicillin blaCTX-M-14
*Antimicrobial non-susceptibility detected by VITEK2. †Blood samples taken before and after the study.
Table 2: Plasmids encoding blaCTX-M-15 or blaCTX-M-14 from PacBio sequencing
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two scenarios. The first was that plasmids carrying 
blaCTX-M-15 shared few segments (mostly over regions 
carrying antibiotic resistance genes) of high identity. We 
also observed the situation where isolates from two 
patients carried identical plasmids but these isolates 
differed by 25 or more SNPs and the patients carrying 
these had weak epidemiological links (appendix 1 p 8).
blaCTX-M-14 was plasmid-borne (all IncB/O/K/Z) in all 
five blaCTX-M-14 positive isolates (four sequence types) from 
two patients (C062 and C047; table 2). blaCTX-M-14 positive 
plasmids from patient C062 were identical (>99% identity 
over >99% coverage), including plasmids from two 
different sequence types, consistent with within-host 
plasmid sharing between sequence types. However, the 
blaCTX-M-14 plasmids from C047 showed great diversity and 
were different to those found in C062. Representative 
blaCTX-M-14 carrying plasmids and plasmid comparisons are 
shown in appendix 1 (pp 11, 20–23) and appendix 2 (p 4).
Discussion
In this study we extensively examined within-host 
diversity by serial sampling 94 patients, which showed 
that almost half of all patients carried more than 
one sequence type and more than 70% of patients 
positive for ESBL-producing E coli were also positive for 
non-ESBL-producing E coli. This finding indicates that 
surveillance and outbreak investigations based on single 
colonies or focused solely on ESBL-producing isolates19,20 
are likely to underestimate transmission events and the 
diversity of antimicrobial susceptibility profiles present 
in a sample. A previous study of 127 genomes from 
eight children, seven of whom were positive for ESBL-
producing E coli, identified a median of four sequence 
types per child (range 1–10).7 Analysing seven ESBL-
producing E coli genomes from three stool samples from 
one patient with cystic fibrosis identified up to three 
sequence types per sample.9
Diversity was also identified within specific sequence 
types. A maximum of 17 SNPs were detected per sequence 
type in each patient, similar to that previously reported 
(12 SNPs) for ST131 isolated from long-term care facility 
residents.8 To date, few studies have investigated within-
host diversity of E coli using sequencing, and these 
studies were small and limited by the inclusion of only 
ESBL-producing strains.
On the basis of genomic data, we identified that almost 
a third of patients appeared to acquire one or more E coli 
sequence types through a total of 50 acquisition events. 
Three of the 50 acquisition events were due to 
ESBL-producing E coli, and in total 34 unique sequence 
types were acquired. A major strength of our study was 
the development of a SNP cutoff to support E coli 
transmission in the studied population. Using a cutoff of 
17 SNPs we found evidence for transmission that was 
restricted to small patient clusters. Additionally, we 
highlight the importance of investigating transmission 
of non-ESBL-producing E coli because eight of ten 
transmission clusters identified in this study were 
non-ESBL-producing E coli, including the two largest 
clusters.
The number of E coli bloodstream infections 
are continuously increasing annually but resistance to 
third-generation cephalosporins accounts for only around 
14% of such infections in the UK, which was why we 
included both ESBL-producing and non-ESBL-producing 
E coli.21 By examining all blood cultures positive for E coli 
from the two haematology wards, we identified a diverse 
collection of invasive strains (19 sequence types) that were 
predominately non-ESBL producers. These results are 
consistent with those observed in a national survey of 
bloodstream infections done between 2001 and 2012 in 
England, in which less than 15% of invasive isolates were 
non-susceptible to third-generation cephalo sporins 
annually compared with 17% of ESBL-producing isolates 
identified in this study.22 Our results are in concordance 
with previous publications that reported ST131 as one of 
the most frequently recovered lineages from bloodstream 
infections in the UK.22–24 All patients with a bloodstream 
infection during this study had a genetically distinct 
strain compared with isolates from other patients 
recruited to the study, but four of seven patients had 
highly similar strains in their blood and stool samples, 
suggesting an endogenous source for the infection.
We also revealed the complexity of investigating the 
transmission of ESBL-producing genes (blaCTX-M-15 
and blaCTX-M-14). Previous studies25 have shown that 
characterisation of large plasmids (>50 kilobase pairs) 
from short-read genome sequence data is challenging 
due to the presence of repeated sequences. In this study, 
all ESBL-producing plasmids were fully characterised 
using long-read sequencing, which provided confidence 
in our conclusions on plasmid structure, genetic context 
of ESBL-encoding genes, and transmission. We found 
that blaCTX-M-15 was commonly integrated into the 
chromosome, unlike in previous studies which showed 
blaCTX-M-15 to be plasmid-encoded.26 Our data show that 
antimicrobial susceptibility data and plasmid replicon 
typing is not sufficient to identify plasmid transmission, 
and long-read sequencing is required to fully understand 
the dissemination of antimicrobial resistance genes.
Our study has several limitations. We sampled less 
than 50% of patients admitted to the two haematology 
wards, and we did not sample the environment or health-
care workers. This sampling strategy might lead to 
underestimated epidemiological links and could explain 
the absence of links between patients carrying highly 
related isolates, the absence of genetic links in putative 
acquisition events, and the inability to identify the source 
of three putative exogenous infections. Additionally, we 
did not sequence the full diversity of E coli in stool 
samples, which can lead to some sequence types being 
misclassified as acquired but instead they might have 
been present at low abundance in previous samples. We 
observed that stool samples contained multiple sequence 
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types, but we cannot exclude that these did not contain 
additional sequence types. Future studies could sequence 
directly from plate sweeps to capture greater diversity 
within individuals. We established a SNP cutoff to infer 
E coli transmission in this cohort of patients admitted 
to hospital. A limitation of this approach is that the 
directionality of transmission cannot be inferred. Also, 
combining epidemiological with genomic data to confirm 
transmission is essential, but this cutoff restricts the 
number of patients requiring detailed epidemiological 
follow-up. Additionally, the dataset and method described 
in this study are of great value to establish a SNP 
threshold, but more datasets from other settings would 
be needed to conclude a universal SNP cutoff.
In conclusion, the findings from our study have 
important implications for carriage, acquisition, and 
transmission analyses of E coli. Our study highlights 
polyclonal E coli colonisation, the value of characterising 
multiple isolates per sample, and the clinical relevance of 
E coli transmission in the hospital setting. Using the 
diversity of the same strains from the same host from 
multipick data we defined a cutoff of clonality that led to 
the identification of putative nosocomial transmission 
of E coli strains driving carriage and bloodstream 
infections in patients admitted to hospital. Using 
long-read sequencing, we identified diverse mechanisms 
of blaCTX-M-15 and blaCTX-M-14 carriage with no evidence of 
plasmid sharing between patients. High diversity was 
observed in bacteraemia isolates, but we identified 
patients with indistinguishable isolates from stool and 
blood samples, suggesting an endogenous infection. 
Future interventions to reduce the number of E coli 
bacteraemia should focus on preventing endogenous 
infections.
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